TISIDB

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Membrane; Peripheral membrane protein; Cytoplasmic side. Mitochondrion membrane; Peripheral membrane protein; Cytoplasmic side. Lipid droplet.
Domain	PF00620 RhoGAP domain PF07647 SAM domain (Sterile alpha motif) PF01852 START domain
Function	GTPase-activating protein for RhoA, and perhaps for Cdc42. May be involved in regulation of cytoskeletal reorganization, cell proliferation and cell motility. Acts a tumor suppressor in hepatocellular carcinoma cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0002040 sprouting angiogenesis GO:0002042 cell migration involved in sprouting angiogenesis GO:0003158 endothelium development GO:0003159 morphogenesis of an endothelium GO:0010594 regulation of endothelial cell migration GO:0010596 negative regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010633 negative regulation of epithelial cell migration GO:0016525 negative regulation of angiogenesis GO:0030336 negative regulation of cell migration GO:0035239 tube morphogenesis GO:0040013 negative regulation of locomotion GO:0043534 blood vessel endothelial cell migration GO:0043535 regulation of blood vessel endothelial cell migration GO:0043537 negative regulation of blood vessel endothelial cell migration GO:0043542 endothelial cell migration GO:0045765 regulation of angiogenesis GO:0048514 blood vessel morphogenesis GO:0051056 regulation of small GTPase mediated signal transduction GO:0051271 negative regulation of cellular component movement GO:0060562 epithelial tube morphogenesis GO:0061154 endothelial tube morphogenesis GO:0090049 regulation of cell migration involved in sprouting angiogenesis GO:0090051 negative regulation of cell migration involved in sprouting angiogenesis GO:0090130 tissue migration GO:0090132 epithelium migration GO:0097498 endothelial tube lumen extension GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1903670 regulation of sprouting angiogenesis GO:1903671 negative regulation of sprouting angiogenesis GO:2000146 negative regulation of cell motility GO:2000181 negative regulation of blood vessel morphogenesis
Molecular Function	GO:0005096 GTPase activator activity GO:0008047 enzyme activator activity GO:0030695 GTPase regulator activity GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component	GO:0005811 lipid particle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-194840: Rho GTPase cycle R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STARD13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STARD13 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STARD13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.872	0.0399
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.438	0.171
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.463	0.602
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.225	0.578
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.564	0.795
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.204	0.941
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.094	0.818
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.175	0.895
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.347	0.819
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.04	0.964
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.781	0.512
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.259	0.0358

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STARD13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	5.5	1.9	0.66
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STARD13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STARD13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STARD13. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STARD13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STARD13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STARD13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STARD13
Name	StAR-related lipid transfer (START) domain containing 13
Aliases	GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ......
Chromosomal Location	13q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STARD13 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse STARD13